Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

Michael Yee has given his Buy rating due to a combination of factors including the recent positive developments regarding Biogen’s Alzheimer’s drug, Leqembi, in the European market. The European ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...